title: Evaluation of amonafide in refractory and relapsing multiple myeloma: a Southwest Oncology Group study.
abstract: This study involved the administration of amonafide intravenously 300 mg/m2 daily times five days every three weeks to 16 refractory and relapsed myeloma patients. Doses were escalated to toxicity. These doses caused severe thrombocytopenia and granulocytopenia in seven patients. No responses were seen in this heavily pretreated group of patients.
authors.affiliation: St. Luke's Hospital, Kansas City, MO.
authors.forename: K H
authors.initials: KH
authors.lastname: Hanson
authors.forename: J
authors.initials: J
authors.lastname: Crowley
authors.forename: S E
authors.initials: SE
authors.lastname: Salmon
authors.forename: M
authors.initials: M
authors.lastname: Keppen
authors.forename: T J
authors.initials: TJ
authors.lastname: Braun
authors.forename: J D
authors.initials: JD
authors.lastname: Bonnet
mesh_terms: D000225:Adenine; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001772:Blood Cell Count; D004351:Drug Resistance; D005260:Female; D006098:Granulocytes / Q000187:drug effects; D006801:Humans; D007094:Imides; D007546:Isoquinolines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007970:Leukopenia / Q000097:blood / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D053644:Naphthalimides; D063065:Organophosphonates; D012008:Recurrence; D013921:Thrombocytopenia / Q000097:blood / Q000139:chemically induced
chemical_list: D000970:Antineoplastic Agents; D007094:Imides; D007546:Isoquinolines; D053644:Naphthalimides; D063065:Organophosphonates; C037020:amonafide; D000225:Adenine